Lantheus (0L8) AI Stock Analysis

7 Followers

Lantheus

(XETRA:0L8)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationRobust operating and free cash flow indicates that Lantheus converts its business activity into funding reliably. This supports investment in radiopharmaceutical capacity, commercial expansion, and strategic initiatives while reducing dependence on external financing over the next several quarters.

Negative Factors

Bottom-line earnings volatilityDeclining net income despite healthy gross and operating margins indicates pressure below the operating line and less consistent bottom-line performance. This volatility can complicate planning, reduce confidence in near-term earnings conversion, and limit the predictability of shareholder returns.

Lantheus (0L8) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.55B
Dividend Yield: ―
Average Volume (3M): 210
Price to Earnings (P/E): 23.9
Beta (1Y): 0.07
Revenue Growth: -4.62%
EPS Growth: 0.96%
Country: Germany
Employees: 1,193
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis an...

Lantheus Earnings Call Summary

Earnings Call Date:May 06, 2026(Q1-2026)|% Change Since:23.18%|Next Earnings Date:Oct 28, 2026

Earnings Call SentimentNeutral

The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.

Positive Updates

FDA Approval of PYLARIFY TRUVU

FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.

Negative Updates

Oncology Revenue Decline (PYLARIFY reported revenue)

Oncology revenue (PYLARIFY) was $240.9 million in Q1, down 6.5% year-over-year despite volume growth, reflecting net price pressure and competitive dynamics in the PSMA PET space.

Company Guidance

Lantheus reiterated full‑year 2026 guidance of $1.40–$1.45 billion in revenue and $5.00–$5.25 in adjusted EPS while citing a strong Q1 start: Q1 revenue $377.3M (+1.2% YoY; +8.6% ex‑$25.2M divested spec revenue), reported net income $118.4M and adjusted net income $95.8M (‑12.5% YoY), GAAP diluted EPS $1.80 and adjusted EPS $1.46 (down ~4.6%), operating profit $129.1M (‑10.5%), gross margin 67.0%, operating expenses 32.8% of revenue, and an effective tax rate of 25.3%; product level Q1 results included PYLARIFY $240.9M (‑6.5% YoY; U.S. volume +5.8% YoY), NEUROCEQ $35.4M (+14.3% vs Q4 2025), DEFINITY $84.6M (+6.8% YoY) and strategic partnerships $16.3M (+52.1%). Cash generation remained strong with operating cash flow $125.1M, capex $3.2M, free cash flow $121.9M, cash & equivalents $498.6M, $200M remaining on the buyback authorization and a $750M undrawn revolver; management said guidance is being maintained out of prudence given competitive dynamics and an upcoming CEO transition, while expecting growth acceleration beginning in 2027.

Lantheus Risk Analysis

Lantheus disclosed 67 risk factors in its most recent earnings report. Lantheus reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Because the value of the contingent value rights ("CVRs") is uncertain, our stockholders cannot be certain of the precise value of the consideration they may receive in the Merger.Q2, 2026

2.We may not, or may take longer to, realize the expected benefits and opportunities related to, the POINT Biopharma Global Inc. ("POINT") License Agreements, including PNT2003.Q2, 2026

3.We may not be successful in identifying a transaction partner or buyer for our radiotherapeutic assets, and the pursuit of strategic alternatives could adversely affect our business.Q2, 2026

Lantheus Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:0L8 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	75Outperform	$1.62B	14.96	19.19%	―	30.90%	―
ETON	70Outperform	$1.45B	109.57	40.13%	―	81.49%	―
AMPH	68Neutral	$1.15B	15.59	10.11%	―	1.02%	-38.09%
PCRX	62Neutral	$1.45B	103.35	2.13%	―	5.71%	―
HCM	57Neutral	$2.30B	141.65	1.43%	―	-8.81%	-96.21%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:0L8 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:0L8	Lantheus Holdings Inc	89.80	40.39	81.74%
PCRX	Pacira	36.39	14.54	66.54%
ANIP	Ani Pharmaceuticals	72.28	-20.34	-21.96%
AMPH	Amphastar Pharmaceuticals Inc	27.12	1.81	7.15%
HCM	Hutchmed (China) Limited	13.08	-2.49	-15.99%
ETON	Eton Pharmaceuticals	50.95	31.70	164.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Lantheus AI Stock Analysis